"Lymphocytes, Tumor-Infiltrating" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Lymphocytes that show specificity for autologous tumor cells. Ex vivo isolation and culturing of TIL with interleukin-2, followed by reinfusion into the patient, is one form of adoptive immunotherapy of cancer.
| Descriptor ID |
D016246
|
| MeSH Number(s) |
A11.118.637.555.567.650 A15.145.229.637.555.567.650 A15.382.490.555.567.650
|
| Concept/Terms |
Lymphocytes, Tumor-Infiltrating- Lymphocytes, Tumor-Infiltrating
- Lymphocytes, Tumor Infiltrating
- Tumor-Infiltrating Lymphocytes
- Lymphocyte, Tumor-Infiltrating
- Tumor Infiltrating Lymphocytes
- Tumor-Infiltrating Lymphocyte
Tumor-Derived Activated Cells- Tumor-Derived Activated Cells
- Activated Cell, Tumor-Derived
- Activated Cells, Tumor-Derived
- Tumor Derived Activated Cells
- Tumor-Derived Activated Cell
|
Below are MeSH descriptors whose meaning is more general than "Lymphocytes, Tumor-Infiltrating".
Below are MeSH descriptors whose meaning is more specific than "Lymphocytes, Tumor-Infiltrating".
This graph shows the total number of publications written about "Lymphocytes, Tumor-Infiltrating" by people in this website by year, and whether "Lymphocytes, Tumor-Infiltrating" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2003 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lymphocytes, Tumor-Infiltrating" by people in Profiles.
-
Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor-Positive Breast Cancer Patients. Clin Cancer Res. 2020 12 15; 26(24):6523-6534.
-
A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. Clin Cancer Res. 2020 04 15; 26(8):1896-1904.
-
Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy. Virchows Arch. 2011 Aug; 459(2):183-91.
-
Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A. 2003 Mar 18; 100(6):3398-403.
-
Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood. 1997 May 15; 89(10):3806-16.
MeSH information
